MedTrace Logo

A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma

NCT05940441 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2023-07-11

No results posted yet for this study

Summary

To explore whether the adjuvant therapy of metronomic capecitabine could improve the disease-free survival of locoregionally advanced hypopharyngeal carcinoma (stage IV：T4N0-1M0，anyTN2-3M0).

Conditions

  • to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma

Interventions

DRUG

Capecitabine 500Mg Oral Tablet

650 mg/m² body surface area twice daily for 1 year

Sponsors & Collaborators

  • Eye & ENT Hospital of Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2025-07-01
Completion
2027-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05940441 on ClinicalTrials.gov